{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:03:13Z","timestamp":1781701393330,"version":"3.54.5"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008812","name":"Defence Science and Technology Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bcp.2025.117616","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T23:47:19Z","timestamp":1765237639000},"page":"117616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel peptide explicitly induces prostate cancer cell death by destabilizing AR and inhibiting AR-mediated transcription"],"prefix":"10.1016","volume":"245","author":[{"given":"Akanksha","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishani","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-7304","authenticated-orcid":false,"given":"Ashish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117616_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2025.117616_b0010","doi-asserted-by":"crossref","first-page":"\u010335","DOI":"10.1101\/cshperspect.a030635","article-title":"Treatment of advanced prostate cancer\u2014A review of current therapies and future promise","volume":"8","author":"Sumanasuriya","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2025.117616_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: Evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bcp.2025.117616_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: From discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117616_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1006101","article-title":"Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.bcp.2025.117616_b0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-017-0568-7","article-title":"Mechanisms of therapeutic resistance in prostate cancer","volume":"19","author":"Nakazawa","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bcp.2025.117616_b0035","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.bcp.2025.117616_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/240108","article-title":"Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management","volume":"2013","author":"Sountoulides","year":"2013","journal-title":"ISRN Urol"},{"key":"10.1016\/j.bcp.2025.117616_b0045","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bcp.2025.117616_b0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/iub.2665","article-title":"Resistance to prostate cancer treatments","volume":"75","author":"Krause","year":"2023","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bcp.2025.117616_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433126","article-title":"Balancing hormone therapy: Mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management","volume":"44","author":"Gudenkauf","year":"2024","journal-title":"American Soc. Clinical Oncology Educational Book"},{"key":"10.1016\/j.bcp.2025.117616_b0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.urolonc.2008.03.021","article-title":"Mechanisms mediating androgen receptor reactivation after castration","volume":"27","author":"Yuan","year":"2009","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1016\/j.bcp.2025.117616_b0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a030452","article-title":"Androgen signaling in prostate cancer","volume":"7","author":"Dai","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.bcp.2025.117616_b0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/er.2002-0032","article-title":"Androgen receptor in prostate cancer","volume":"25","author":"Heinlein","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2025.117616_b0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/aja.2010.89","article-title":"Androgen receptor signaling and mutations in prostate cancer","volume":"12","author":"Koochekpour","year":"2010","journal-title":"Asian J. Androl."},{"key":"10.1016\/j.bcp.2025.117616_b0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/0115748871260733231031081921","article-title":"A review of clinical trials of cancer and its treatment as a vaccine","volume":"19","author":"Chandarana","year":"2024","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.bcp.2025.117616_b0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40610-018-0095-9","article-title":"Epigenetic regulation in prostate cancer progression","volume":"4","author":"Ruggero","year":"2018","journal-title":"Curr. Mol. Biol. Rep."},{"key":"10.1016\/j.bcp.2025.117616_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/cancers9010009","article-title":"Epigenomic regulation of androgen receptor signaling: Potential role in prostate cancer therapy","volume":"9","author":"Cucchiara","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117616_b0095","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117616_b0100","doi-asserted-by":"crossref","first-page":"36865","DOI":"10.1074\/jbc.R100041200","article-title":"Coregulator codes of transcriptional regulation by nuclear receptors","volume":"276","author":"Rosenfeld","year":"2001","journal-title":"J. Bio. Chem."},{"key":"10.1016\/j.bcp.2025.117616_b0105","doi-asserted-by":"crossref","first-page":"T23","DOI":"10.1530\/JME-13-0227","article-title":"An evolving understanding of nuclear receptor coregulator proteins","volume":"51","author":"Millard","year":"2013","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.bcp.2025.117616_b0110","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2016.04.012","article-title":"TRIM24 is an oncogenic transcriptional activator in prostate cancer","volume":"29","author":"Groner","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2025.117616_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.886594","article-title":"Lysine acetyltransferases and their role in AR signaling and prostate cancer","volume":"13","author":"Jaiswal","year":"2022","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.117616_b0120","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/epi.10.31","article-title":"Histone modifications and chromatin organization in prostate cancer","volume":"2","author":"Chen","year":"2010","journal-title":"Epigenomics"},{"key":"10.1016\/j.bcp.2025.117616_b0125","doi-asserted-by":"crossref","unstructured":"Agoulnik, I. U. & Weigel, N. L. Androgen Receptor Coactivators and Prostate Cancer. in 245\u2013255 (2008). doi:10.1007\/978-0-387-69080-3_23.","DOI":"10.1007\/978-0-387-69080-3_23"},{"key":"10.1016\/j.bcp.2025.117616_b0130","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.steroids.2009.02.007","article-title":"Coactivator selective regulation of androgen receptor activity","volume":"74","author":"Agoulnik","year":"2009","journal-title":"Steroids"},{"key":"10.1016\/j.bcp.2025.117616_b0135","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/cancers14102402","article-title":"Nuclear receptor coregulators in hormone-dependent cancers","volume":"14","author":"Jafari","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117616_b0140","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/er.2007-0019","article-title":"Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex","volume":"28","author":"Heemers","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bcp.2025.117616_b0145","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/sj.onc.1206342","article-title":"Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development","volume":"22","author":"Halkidou","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2025.117616_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jmcb\/mjw038","article-title":"TIP60 inhibits metastasis by ablating DNMT1\u2212SNAIL2-driven epithelial-mesenchymal transition program","volume":"8","author":"Zhang","year":"2016","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117616_b0155","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2217\/epi.15.76","article-title":"A bivalent role of TIP60 histone acetyl transferase in human cancer","volume":"7","author":"Judes","year":"2015","journal-title":"Epigenomics"},{"key":"10.1016\/j.bcp.2025.117616_b0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/2211-5463.12371","article-title":"Tip60 is associated with resistance to X\u2010ray irradiation in prostate cancer","volume":"8","author":"Xie","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.bcp.2025.117616_b0165","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.3390\/ijms21186622","article-title":"Metabolic roles of androgen receptor and tip60 in androgen-dependent prostate cancer","volume":"21","author":"Tan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117616_b0170","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.breast.2023.04.001","article-title":"The effect of silencing the Tip60 gene on the response to radiotherapy in breast cancer cells","volume":"69","author":"Miser-Saliho\u011flu","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2025.117616_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045539","article-title":"Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer","volume":"7","author":"Coffey","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2025.117616_b0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tcb.2006.07.007","article-title":"Tip60 in DNA damage response and growth control: many tricks in one HAT","volume":"16","author":"Squatrito","year":"2006","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2025.117616_b0185","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.biocel.2006.03.003","article-title":"Cellular functions of TIP60","volume":"38","author":"Sapountzi","year":"2006","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117616_b0190","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1210\/en.2017-03190","article-title":"Modulation of nuclear receptor function by chromatin modifying factor TIP60","volume":"159","author":"Jaiswal","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2025.117616_b0195","doi-asserted-by":"crossref","first-page":"46841","DOI":"10.1074\/jbc.M103710200","article-title":"Tip60 is a Co-activator specific for class I Nuclear hormone receptors","volume":"276","author":"Gaughan","year":"2001","journal-title":"J. Bio. Chem."},{"key":"10.1016\/j.bcp.2025.117616_b0200","doi-asserted-by":"crossref","first-page":"25904","DOI":"10.1074\/jbc.M203423200","article-title":"Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor","volume":"277","author":"Gaughan","year":"2002","journal-title":"J. Bio. Chem."},{"key":"10.1016\/j.bcp.2025.117616_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102015","article-title":"TIP60 acts as a regulator of genes involved in filopodia formation and cell migration during wound healing","volume":"298","author":"Dubey","year":"2022","journal-title":"J. Bio. Chem."},{"key":"10.1016\/j.bcp.2025.117616_b0210","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2025.117616_b0215","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12935-022-02553-7","article-title":"Investigating the role of peptides in effective therapies against cancer","volume":"22","author":"Naeimi","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2025.117616_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114832","article-title":"Evolving strategies and application of proteins and peptide therapeutics in cancer treatment","volume":"163","author":"Mukherjee","year":"2023","journal-title":"Biomedicine Pharmacotherapy"},{"key":"10.1016\/j.bcp.2025.117616_b0225","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/ds16-0026","article-title":"Glucagon-like peptide 1 receptor agonists for type 2 diabetes","volume":"30","author":"Hinnen","year":"2017","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.bcp.2025.117616_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The Discovery and Development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.bcp.2025.117616_b0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/apt.12604","article-title":"Review article: linaclotide for the management of irritable bowel syndrome with constipation","volume":"39","author":"Layer","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117616_b0240","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1038\/s41598-017-03783-w","article-title":"Novel complex of HAT protein TIP60 and nuclear receptor PXR promotes cell migration and adhesion","volume":"7","author":"Bakshi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2025.117616_b0245","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1107\/S0021889892009944","article-title":"PROCHECK: a program to check the stereochemical quality of protein structures","volume":"26","author":"Laskowski","year":"1993","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.bcp.2025.117616_b0250","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/pro.5560020916","article-title":"Verification of protein structures: Patterns of nonbonded atomic interactions","volume":"2","author":"Colovos","year":"1993","journal-title":"Protein Sci."},{"key":"10.1016\/j.bcp.2025.117616_b0255","doi-asserted-by":"crossref","unstructured":"Eisenberg, D., L\u00fcthy, R. & Bowie, J. U. [20] VERIFY3D: Assessment of protein models with three-dimensional profiles. in 396\u2013404 (1997). doi:10.1016\/S0076-6879(97)77022-8.","DOI":"10.1016\/S0076-6879(97)77022-8"},{"key":"10.1016\/j.bcp.2025.117616_b0260","doi-asserted-by":"crossref","first-page":"W407","DOI":"10.1093\/nar\/gkm290","article-title":"ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins","volume":"35","author":"Wiederstein","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2025.117616_b0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10822-010-9395-8","article-title":"Computer-aided drug design platform using PyMOL","volume":"25","author":"Lill","year":"2011","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bcp.2025.117616_b0270","doi-asserted-by":"crossref","DOI":"10.1385\/1-59259-890-0:571","article-title":"Protein identification and analysis tools on the ExPASy server","volume":"571\u2013607","author":"Gasteiger","year":"2005","journal-title":"The Proteomics Protocols Handbook"},{"key":"10.1016\/j.bcp.2025.117616_b0275","unstructured":"BIOVIA & Dassault Syst{\\\u2018e}mes. Discovery studio 2021 client, San Diego: Dassault Syst{\\\u2018e}mes. Discovery studio (2021)."},{"key":"10.1016\/j.bcp.2025.117616_b0280","doi-asserted-by":"crossref","first-page":"33225","DOI":"10.18632\/oncotarget.16600","article-title":"The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2\/Cyclin a interaction using computational approaches","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2025.117616_b0285","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/prot.21373","article-title":"ZRANK: reranking protein docking predictions with an optimized energy function","volume":"67","author":"Brain","year":"2007","journal-title":"Proteins: Structure, Function, Bioinformatics"},{"key":"10.1016\/j.bcp.2025.117616_b0290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/jcc.540040211","article-title":"CHARMM : A program for macromolecular energy, minimization, and dynamics calculations","volume":"4","author":"Brooks","year":"1983","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bcp.2025.117616_b0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/prot.10389","article-title":"ZDOCK: an initial\u2010stage protein\u2010docking algorithm","volume":"52","author":"Chen","year":"2003","journal-title":"Proteins Struct. Funct. Bioinf."},{"key":"10.1016\/j.bcp.2025.117616_b0300","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/prot.10460","article-title":"RDOCK: refinement of rigid\u2010body protein docking predictions","volume":"53","author":"Li","year":"2003","journal-title":"Proteins Struct. Funct. Bioinf."},{"key":"10.1016\/j.bcp.2025.117616_b0305","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cpt.256","article-title":"Androgen receptor targeting drugs in castration\u2010resistant prostate cancer and mechanisms of resistance","volume":"98","author":"Crona","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117616_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101115","article-title":"Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease","volume":"14","author":"Maylin","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.bcp.2025.117616_b0315","article-title":"Anti-androgen receptor therapies in prostate cancer: A brief update and perspective","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2025.117616_b0320","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/138920209787581307","article-title":"The role of androgen receptor mutations in prostate cancer progression","volume":"10","author":"Brooke","year":"2009","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.bcp.2025.117616_b0325","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bcp.2025.117616_b0330","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2025.117616_b0335","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168649","article-title":"Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs","volume":"134","author":"Han","year":"2024","journal-title":"J. Clinical Investigation"},{"key":"10.1016\/j.bcp.2025.117616_b0340","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3390\/cells10112908","article-title":"Novel peptide therapeutic approaches for cancer treatment","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2025.117616_b0345","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bcp.2025.117616_b0350","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/ncomms2912","article-title":"Peptidomimetic targeting of critical androgen receptor\u2013coregulator interactions in prostate cancer","volume":"4","author":"Ravindranathan","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2025.117616_b0355","first-page":"2892","article-title":"Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen}","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117616_b0360","first-page":"366","article-title":"Mechanisms and targeting of proteosome-dependent androgen receptor degradation in prostate cancer","volume":"10","author":"Fang","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.bcp.2025.117616_b0365","first-page":"663","volume":"16","author":"Chen","year":"2024","journal-title":"Insight into Recent Adv. Degrading Androgen Receptor for Castration-Resistant Prostate Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:22:40Z","timestamp":1781698960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225008810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":73,"alternative-id":["S0006295225008810"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117616","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel peptide explicitly induces prostate cancer cell death by destabilizing AR and inhibiting AR-mediated transcription","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117616"}}